Target Serum Urate Achievement and Chronic Kidney Disease Progression in Patients With Gout and Kidney Disease
2024

How Lowering Uric Acid Levels Affects Kidney Disease in Gout Patients

Sample size: 14792 publication 10 minutes Evidence: high

Author Information

Author(s): Wang Yilun MD PhD, Dalbeth Nicola MD, Terkeltaub Robert MD, Zhang Yuqing DSc, Li Xiaoxiao MS, Zeng Chao MD PhD, Lei Guanghua MD PhD, Wei Jie PhD

Primary Institution: Xiangya Hospital, Central South University, Changsha, China

Hypothesis

How does urate-lowering therapy (ULT) affect the progression of chronic kidney disease (CKD) in patients with gout and impaired kidney function?

Conclusion

Lowering serum urate levels to less than 6 mg/dL in patients with gout and CKD stage 3 does not increase the risk of severe or end-stage kidney disease.

Supporting Evidence

  • The study included 14,792 patients with gout and CKD stage 3.
  • The 5-year risk of severe or end-stage kidney disease was 10.32% for those achieving target urate levels.
  • The adjusted hazard ratio for severe or end-stage kidney disease was 0.89.

Takeaway

This study shows that lowering uric acid levels in gout patients with kidney problems is safe and doesn't make their kidneys worse.

Methodology

This cohort study used data from a general practice database to evaluate the association between achieving target serum urate levels and CKD progression.

Potential Biases

Potential selection bias and confounding by indication may affect the results.

Limitations

Residual confounding cannot be ruled out, and the generalizability may be limited due to exclusion criteria.

Participant Demographics

Mean age was 73.1 years, with 62.3% men and 37.7% women.

Statistical Information

P-Value

<0.001

Confidence Interval

95% CI, −4.61% to −0.21%

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1001/jamainternmed.2024.6212

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication